Dokument: 68Ga- or 18F-FAPI PET/CT—what it can and cannot

Titel:	68Ga- or 18F-FAPI PET/CT—what it can and cannot
URL für Lesezeichen:	https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=68594
URN (NBN):	urn:nbn:de:hbz:061-20250212-132754-7
Kollektion:	Publikationen
Sprache:	Englisch
Dokumententyp:	Wissenschaftliche Texte » Artikel, Aufsatz
Medientyp:	Text
Autoren:	Mori, Yuriko [Autor] Haberkorn, Uwe [Autor] Giesel, Frederik L. [Autor]
Dateien:	[Dateien anzeigen] Adobe PDF [Details] 409,4 KB in einer Datei [ZIP-Datei erzeugen] Dateien vom 12.02.2025 / geändert 12.02.2025
Beschreibung:	Recent innovation in nuclear medicine has led to the introduction of a novel class of ligands, named fibroblast activation protein inhibitors (FAPIs) [1,2,3]. In contrast to tumor entity-specific imaging strategies such as prostate-specific membrane antigen (PSMA) ligand–based PET, FAPI-PET is based on the universal approach of targeting the activated fibroblasts (cancer-associated fibroblasts: CAFs) which primarily addresses the cancer stroma (tumor microenvironment). Fibroblast activation protein (FAP) is a membrane-bound type 2 serine protease, which is overexpressed in activated fibroblasts. Through the specific binding to the enzymatic domain of FAP, FAPI-PET is able to visualize the tumor stroma formation as small as 2–3 mm [4]. In comparison to conventional PET imaging like FDG-PET, FAPI-PET is characterized by high image contrast, resulting from the low background signal in the normal organs, due to the low expression or FAP in the normal, quiescent fibroblasts.
Rechtliche Vermerke:	Originalveröffentlichung: Mori, Y., Haberkorn, U., & Giesel, F. L. (2023). 68Ga- or 18F-FAPI PET/CT—what it can and cannot. European Radiology, 33(11), 7877–7878. https://doi.org/10.1007/s00330-023-09715-9
Lizenz:	Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz
Fachbereich / Einrichtung:	Medizinische Fakultät
Dokument erstellt am:	12.02.2025
Dateien geändert am:	12.02.2025